Since Gentles' discovery1 that griseofulvin, an antibiotic isolated from Penicillium griseofulvum and studied 19 years before,2 was effective in shortening the severity and duration of experimental dermatophytosis in guinea pigs, this therapeutic agent has had remarkably prompt, thorough, and eminently successful clinical trials. It is an ideal specific treatment for dermatophytosis because it is nontoxic at therapeutic doses, is administered orally, and it accumulates in fungistatic concentrations in the keratinized tissues which are attacked by the dermatophytes.3 Although griseofulvin is less active in vitro against the fungi which cause systemic mycoses than against the dermatophytes, tests of its therapeutic effect upon experimental systemic mycoses were obviously indicated.
Materials and Methods
General purpose, female, Swiss, white mice weighing 17-20 gm. were infected by injection into a tail vein of cell or spore suspensions of fungi, using the type of mouse holder designed by Feber4 in this
EMMONS CW. Failure of Griseofulvin to Control Experimental Systemic Mycoses in Mice. AMA Arch Derm. 1960;81(5):700–702. doi:10.1001/archderm.1960.03730050056010
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.